SRF Limited: Specialty Chemicals Compounder Re-Rated, Yet Still Under-Owned — A High-Conviction Allocation at ₹2,743

NSE: SRF | BSE: 503806 | Sector: Chemicals (Specialty + Technical Textiles) | CMP: ₹2,743 | Market Cap: ₹81,293 Cr | 52W High/Low: ₹3,325 / ₹1,818 | Stock P/E: 42.7x | ROCE: 14.6% | ROE: 14.3% | Book Value: ₹474 | Dividend Yield: 0.33% | Face Value: ₹10

Section 1 — Executive Summary & Investment Thesis

SRF Limited (NSE: SRF, BSE: 503806) is one of India's most diversified and quietly powerful specialty chemicals and technical textiles platforms — a multi-decade compounder that has compounded consolidated revenue at a 13% CAGR over the last 10 years and net profit at ~20% CAGR over the same window, while building a portfolio of fluorochemicals, specialty gases, engineering plastics, polyester films, technical textiles, and coated fabrics that touches industries as varied as pharmaceuticals, refrigerants, EV batteries, solar modules, food packaging, automotive airbags, and tire reinforcement. At a CMP of ₹2,743, a market capitalization of ₹81,293 Cr, a Stock P/E of 42.7x, a ROCE of 14.6%, an ROE of 14.3%, and a Book Value of ₹474 per share, SRF is no longer the small-cap chemicals Cinderella it was a decade ago, but the central argument of this report is that the market is still under-pricing three structural drivers: (1) the post-MPPCEA global re-organisation of fluorochemical supply chains in which SRF is the only Indian player at scale, (2) the pharma and agrochemical CDMO tailwind that is converting SRF's intermediates and actives pipeline into a multi-year revenue annuity, and (3) the battery chemicals and specialty gas optionality that has not yet been capitalised into consensus numbers.

The headline numbers, refreshed off Screener.in's consolidated page, are:

The single-line thesis: SRF is a ₹81,293 Cr specialty chemicals platform with a five-pillar portfolio, a 13% 10-year revenue CAGR, a 14-15% blended ROCE, a fortress balance sheet, and three secular growth optionalities (fluoropolymers, pharma CDMO, battery chemicals) that are not in FY27E numbers. Patient capital should be allocated, scaled in tranches, and held through the inevitable fluorochemical cycle troughs.

The single-line risk: SRF carries gross debt of ₹5,083 Cr against equity of ₹14,042 Cr, runs a working capital cycle of 69 days, and the specialty chemicals segment is exposed to global HFC/HFO pricing, agrochemical order-book timing, and the Chinese competitive overhang on commodity fluoropolymers.

Section 2 — Business Description & Revenue Mix

SRF Limited is a Gurugram-headquartered, KMP-family-controlled specialty chemicals and technical textiles conglomerate, originally founded in 1970 as Shri Ram Fibres and listed on the Bombay Stock Exchange in the early 1970s. The company has, over five decades, evolved from a single nylon tyre cord fabric manufacturer into a five-pillar, multi-vertical platform that operates 13 manufacturing locations across India (Bhiwadi, Dahej, Manali, Pantnagar, Malanpur, Kashipur, Bhopal, Viralimalai, Gummidipoondi, Ambernath), Thailand, South Africa, Hungary, and Italy, employs more than 7,500 people, and serves customers in over 75 countries.

The current five-pillar portfolio breaks down as follows:

The fluorochemicals pillar is the crown jewel. SRF operates India's largest integrated fluorochemicals complex at Dahej, Gujarat and a second major complex at Bhiwadi, Rajasthan, with combined HFC-134a, HFC-32, HFC-125, HFC-410A blend, HFO-1234yf, HFO-1234ze capacity that makes it the only Indian player of global scale in the post-Montreal Protocol and post-MPPCEA (Kigali Amendment) refrigerant landscape. SRF also manufactures pharma-grade fluorinated intermediates (used in sitagliptin, empagliflozin, glecaprevir, lenalidomide, and other blockbuster API synthesis routes) and agro intermediates (used in fipronil, flonicamid, fluazinam, and other active ingredients). The fluoropolymers line — FKM (Viton substitutes), PVDF, FEP, PTFE grades — is the new growth frontier, and SRF is one of a handful of non-Chinese, non-Japanese players with deep C2/C3/CF2/CF3 chemistry capability.

The specialty polyester films pillar is centred on BOPET (biaxially-oriented polyethylene terephthalate) films in plain, metalised, coated, and high-barrier grades, produced at Indore (MP), Kashipur (Uttarakhand), and Ambernath (Maharashtra). The films business is a cash cow with strong solar backsheet, EV battery insulation, and high-barrier food packaging tailwinds, and contributes disproportionately to SRF's working capital efficiency.

The technical textiles pillar is the legacy business — nylon tyre cord fabric (NTCF), polyester tyre cord fabric (PTCF), and treated fabrics for conveyor belts and hoses — and serves global tire OEMs (Apollo, MRF, CEAT, JK Tyre, Bridgestone, Continental, Michelin, Goodyear), conveyor belt manufacturers, and industrial sewing thread customers. While this is a low-growth, high-volume, ROE-accretive segment, it is also a defensive one with high replacement-cycle visibility.

The chemicals (commodity) pillar produces chloroform, methylene chloride (MDC), perchloroethylene (PCE), hydrogen peroxide, and aluminium chloride, and serves pharma, water treatment, and dry cleaning end-markets. This pillar is the cyclical ballast in the portfolio — when refrigerant pricing is weak, the chlorinated solvents business is often strong, and vice versa.

The engineering plastics and coated fabrics pillar is a smaller but high-growth segment focused on nylon compounds, polycarbonate compounds, ABS compounds, and PU/PVC coated fabrics for automotive, electrical, and apparel customers.

The geographic mix is approximately 45-50% India, 25-28% Europe, 12-15% North America, 8-10% Asia ex-India, and 2-3% RoW, with exports contributing ~55% of consolidated revenue. The customer base is highly diversified with no single customer accounting for more than 5% of consolidated revenue, which is a structural moat in itself.

Section 3 — 12-Year Consolidated Financial Track Record (FY14-FY25)

The single most important fact about SRF is that it has compounded consolidated revenue from ₹4,540 Cr in FY14 to ₹15,787 Cr in FY25 — a 3.5x revenue scale-up over 12 years — while simultaneously expanding operating margins from 16% to 22% and net profit from ₹303 Cr to ₹1,835 Cr — a 6.1x profit scale-up. This is classic compounder math: revenue compounded at ~11% CAGR and profits at ~16% CAGR, with the gap explained by margin expansion and operating leverage.

The full 12-year track record, lifted off the Screener.in consolidated page, is reproduced below:

The three most important observations from this table:

First, the 5-year revenue CAGR (FY20-FY25) is 13.5% and the 5-year EPS CAGR is 8.9% — i.e., the last 5 years saw revenue grow faster than EPS, which is the opposite of the FY14-FY20 era when EPS grew faster than revenue. This is a classic late-stage-capex digestion pattern: SRF raised gross block from ~₹6,000 Cr in FY20 to ~₹14,000 Cr in FY25, and the resulting depreciation drag + interest cost has temporarily suppressed EPS growth below revenue growth. As utilisation of the Bhiwadi, Dahej, and Indore brownfield expansions ramps, the operating leverage will reverse: revenue and EPS growth will re-converge, and the 3-year EPS CAGR could double from 8.9% to 15-17% by FY27-FY28.

Second, the FY21 and FY22 peak in EPS (₹63.72 and ₹72.95) is unlikely to be a permanent ceiling. The FY21-FY22 peak was driven by a post-COVID global HFC pricing bubble (HFC-134a prices spiked to ₹600+/kg from a normal ₹200-250/kg) and agri-intermediate supply tightness. Those tailwinds have since normalised, and the FY25 EPS of ₹61.91 is now within 15% of the FY22 peak — implying that SRF is on the verge of a fresh EPS leg-up driven by HFO capacity additions, fluoropolymer scale-up, and pharma CDMO growth.

Third, the dividend payout has been disciplined at 8-26%, with SRF retaining the majority of profits for capex and growth. The FY25 dividend per share of ₹9.3 translates to a dividend yield of 0.33% at the current CMP — not a yield story, but a growth reinvestment story.

The growth quality can be decomposed as follows:

Section 4 — Margin Trajectory, Cost Structure & Operating Leverage

SRF's consolidated operating margin has been volatile, ranging from 16% (FY14) to 25% (FY20, FY21) and back to 22% (FY25), reflecting the cyclical nature of fluorochemical pricing and the timing of capex-driven depreciation hits. The FY25 OPM of 22% is 400 bps above the FY14 starting point of 16%, but is still 300 bps below the FY20-FY21 peak of 25% — i.e., there is headroom for further OPM expansion if the fluoropolymer and pharma intermediates mix continues to shift up the value chain.

The cost structure is dominated by raw materials (estimated 55-60% of revenue) — primarily fluorite (CaF2), chloroform, ethylene, propylene, aniline, paraxylene, PTA, MEG, adipic acid, caprolactam, and various fluorinated building blocks — followed by power and fuel (~7-9%), employee costs (~7-9%), freight and handling (~3-4%), depreciation (~5-5.5% in FY25, up from 3.4% in FY14 as the gross block has expanded 3.5x), and interest (~1.8% of revenue in FY25, up from 3.0% in FY14 reflecting the FY20-FY24 capex cycle).

The depreciation-to-sales ratio is a critical metric for SRF investors. The 12-year history is:

The depreciation cycle has likely peaked at ~₹852 Cr in FY25 and is expected to plateau at ₹950-1,000 Cr by FY27-FY28 before tapering as the FY23-FY25 capex wave ages. This is a materially positive setup for EPS expansion: if revenue grows at 12-14% and depreciation grows at 5-7%, the incremental revenue flows almost entirely to operating profit.

The interest cost has tracked the gross debt as follows:

The interest cost peaked in FY24 at ₹376 Cr and fell to ₹278 Cr in FY25 as SRF refinanced high-cost debt and deleveraged the balance sheet. The effective interest rate of 5.5% in FY25 is manageable and well below the ROCE of 14.6%, implying positive financial leverage even on a net debt to EBITDA of ~1.1x.

Section 5 — Balance Sheet, Working Capital & Capital Returns

SRF's balance sheet has been a fortress throughout the 12-year window, with net worth compounding from ₹2,296 Cr in FY14 to ₹14,042 Cr in FY25 — a 6.1x expansion — and total assets scaling from ₹5,883 Cr to ₹24,097 Cr — a 4.1x expansion. The 12-year balance sheet snapshot is:

Three observations from the balance sheet:

First, the equity capital jumped 5x in FY21 (from ₹60 Cr to ₹297 Cr) due to a 1:4 bonus issue. This was a liquidity-enhancing event and brought the free float to a more institutional-friendly 49.74%. The per-share metrics have been retrospectively adjusted for this bonus issue in all historical EPS series.

Second, the fixed-asset base has grown from ₹3,922 Cr to ₹13,926 Cr (3.5x) while the CWIP has grown from ₹104 Cr to ₹1,889 Cr (18.2x) — the latter is the future EPS sitting on the balance sheet, awaiting commissioning and stabilisation. The CWIP of ₹1,889 Cr in FY25 represents ~13.5% of total assets and is a clear forward earnings catalyst as projects move from CWIP to Fixed Assets and start depreciating and contributing to revenue.

Third, the borrowings have grown only 2.1x (from ₹2,435 Cr to ₹5,083 Cr) over 12 years, while net worth has grown 6.1x. The debt-to-equity ratio has fallen from 1.06x in FY14 to 0.36x in FY25 — a massive deleveraging. The gearing is now in the comfortable zone and provides ample headroom for the next capex cycle without requiring fresh equity dilution.

The working capital metrics are reproduced below for the 12-year period:

The CCC has expanded from 75 days (FY14) to 69 days (FY25) — i.e., a modest improvement of 6 days despite the 2.1x debt growth and 4.1x asset growth. The negative working capital days (i.e., negative net working capital as a % of sales) reflect SRF's strong vendor credit and advance customer payments in the fluorochemicals and BOPET films businesses.

The ROCE has been highly cyclical, ranging from 11% (FY14, FY17) to 24% (FY21) and currently at 15% (FY25). The 3-year average ROCE of 13.3% (FY23-FY25) is below the 10-year average of 15.0%, which reflects the capex digestion phase. The forward ROCE is expected to re-rate to 17-19% by FY27-FY28 as the new capex ramps and the depreciation cycle plateaus.

The capital allocation track record is summarised below:

The capital allocation scorecard is strong: ~58% reinvested in capex, ~11% returned to shareholders via dividends, and the balance retained in the business to strengthen the balance sheet and fund working capital. There has been no major M&A — SRF has been an organic compounder, not a roll-up story.

Section 6 — Cash Flow Quality & Free Cash Flow Generation

Cash flow quality is the sleeper strength of the SRF story. The 12-year consolidated cash flow record, lifted from Screener.in, is:

The three most important cash flow observations:

First, the average CFO/OP of 92% is exceptional — most specialty chemicals companies operate at 70-85% CFO/OP, and SRF is at the top of the peer band. The FY25 CFO of ₹2,554 Cr is 90% of operating profit of ₹3,410 Cr, indicating minimal working capital leakage and strong cash conversion.

Second, the cumulative free cash flow of ~₹2,553 Cr over 12 years is modest vs. cumulative net profit of ~₹13,000 Cr, but this is deliberate — SRF has chosen to reinvest ~78% of profits in capex. The capex intensity has averaged ~14% of sales and has ranged from 10% (FY24, FY25) to 21% (FY17). The FY24 and FY25 capex intensity of 10.1% is the lowest in 12 years and suggests that the capex cycle is plateauing and FCF will inflect higher from FY26 onwards.

Third, the FY24 free cash flow of ₹1,265 Cr (101% conversion of net profit) and FY25 FCF of ₹747 Cr (41% conversion) are the highest absolute FCF numbers in the company's history — a clear sign that the capex wave is rolling off and the business is entering a cash harvest phase.

The net cash flow has been broadly neutral across the 12 years (+₹516 Cr cumulative), reflecting the disciplined balance between CFO generation, capex reinvestment, and dividend + debt repayment.

The free cash flow outlook is materially positive: assuming FY26 revenue of ₹17,500 Cr (+11%), capex of ₹1,600 Cr (9% of sales, down from 10.1% in FY25), and net profit of ₹2,000 Cr, the implied FCF could be ₹1,200-1,400 Cr — i.e., a 60% FCF / net profit conversion, and the highest absolute FCF in the company's history. This is the cash engine that will eventually fund a step-up in dividend payout, a buyback, or a strategic acquisition.

Section 7 — Peer Comparison & Competitive Positioning

SRF operates in multiple specialty chemicals sub-segments with different peer sets for each pillar. The most relevant peer comparisons for the fluorochemicals + specialty chemicals business are Navin Fluorine (NAVINFLUOR), Gujarat Fluorochemicals (GFL, part of Inox group), and Aarti Industries (AARTIIND); for the specialty films business the relevant peers are Cosmo Films, Uflex, Jindal Poly Films, and Polyplex Corporation; for the technical textiles business the relevant peers are Century Enka, Pil Italica, and Garware Technical Fibres; and for the commodity chemicals business the relevant peers are Tata Chemicals, Aditya Birla Chemicals, and Meghmani Organics. The closest composite peer — given SRF's portfolio mix — is Aarti Industries, Navin Fluorine, and Atul Corp (ATUL).

The peer comparison table below uses Screener.in data for the most recent reported fiscal year:

Reading the table:

SRF trades at a ~30% P/E premium to the peer median of ~33x, but the premium is justified by three structural advantages that the peer set does not match:

First, SRF's revenue base (₹15,787 Cr) is 2-3x the next-largest specialty chemical peer (Aarti Industries at ~₹7,000 Cr, PI Industries at ~₹7,500 Cr, Gujarat Fluorochem at ~₹6,000 Cr). This scale moat in fluorochemicals + films + technical textiles is unique — no other Indian company has this combination.

Second, SRF's product diversification is the deepest in the peer set: 5 pillars × 13 manufacturing locations × 75+ countries × ~10,000+ SKUs. Aarti Industries is concentrated in nitration, chlorination, and specialty intermediates; Navin Fluorine is concentrated in fluorine chemistry; PI Industries is concentrated in agrochem CSM (custom synthesis); Atul Corp is concentrated in dyes, intermediates, and crop protection chemicals. SRF is the only "multi-pillar" platform in the Indian specialty chemicals universe.

Third, SRF's dividend yield (0.33%) is below the peer median (0.4%) — i.e., SRF is a growth reinvestment story, not a yield story. Investors who want a higher dividend yield should look at Atul Corp (0.8%) or PI Industries (0.4%), but they will sacrifice the optionality of battery chemicals + HFO + fluoropolymers that SRF uniquely offers.

The competitive positioning matrix is summarised as follows:

Section 8 — Segment Deep Dive: Fluorochemicals, Films, Technical Textiles, Chemicals

8.1 Fluorochemicals & Specialty Chemicals — The Crown Jewel

The fluorochemicals and specialty chemicals segment is SRF's largest, most profitable, and most strategically important pillar. The segment encompasses:

(a) HFC Refrigerants (Hydrofluorocarbons): SRF is the largest Indian manufacturer of HFC-134a, HFC-32, HFC-125, HFC-410A blend, HFC-407C blend, and HFC-404A blend with a combined capacity of ~40,000-45,000 TPA (tonnes per annum) across its Dahej and Bhiwadi complexes. The end-customers are AC OEMs (Voltas, LG, Daikin, Blue Star, Hitachi, Carrier, Midea, Haier), refrigerator manufacturers (Whirlpool, Samsung, LG, Godrej), and cold-chain logistics players. The post-MPPCEA (Montreal Protocol + Kigali Amendment) phase-down of HFCs in developed markets (85% phase-down by 2036) and the corresponding GWP (Global Warming Potential)-based quotas create a structural pricing tailwind for SRF as developed-market HFC producers (Honeywell, Chemours, Mexichem, Daikin) are forced to retire HFC capacity, freeing up premium pricing in the residual HFC market for the remaining players (SRF, Arkema, AGC).

(b) HFO Refrigerants (Hydrofluoroolefins): SRF is one of the first Indian companies to commercialize HFO-1234yf and HFO-1234ze — the next-generation, low-GWP (<1) refrigerants that are mandated by EU F-Gas Regulation, US AIM Act, India Kigali Implementation, and Japan / Korea F-Gas rules. The HFO-1234yf global market is estimated at ~150,000 TPA growing at 15-18% CAGR as automotive AC transitions to HFO-1234yf and stationary AC transitions to HFO-32 / HFO-1234yf blends. SRF's HFO capacity at Bhiwadi (~5,000 TPA, expandable to 15,000 TPA) is one of only 4-5 commercial HFO plants globally (alongside Honeywell, Chemours, Daikin, AGC).

(c) Fluoropolymers: SRF manufactures FKM (fluoroelastomers, Viton substitutes) for high-temperature sealing, PVDF (polyvinylidene fluoride) for lithium-ion battery binders and backsheets, FEP (fluorinated ethylene propylene) for wire insulation, and select PTFE (polytetrafluoroethylene) grades. The FKM market is ~50,000 TPA globally growing at 6-8%, the PVDF market is ~150,000 TPA globally growing at 12-15% (driven by lithium-ion battery cathode binder demand and solar PV backsheet demand), and the FEP market is ~30,000 TPA growing at 5-6%. SRF is positioning itself as the only Indian / South Asian integrated fluoropolymer producer with upstream HF, HCFC-22, HFP, VDF, and HFPO integration.

(d) Pharma Intermediates: SRF is a top-3 Indian fluorinated pharma intermediates player and a key custom synthesis partner for global innovator pharma companies (including the top-5 global generic APIs and several Japanese / US innovator APIs). The pharma intermediates portfolio includes fluorinated building blocks for sitagliptin, empagliflozin, glecaprevir, pibrentasvir, lenalidomide, pomalidomide, ibrutinib, abiraterone, enzalutamide, apixaban, rivaroxaban, and ~30 other blockbuster API routes. The CDMO (Contract Development and Manufacturing Organization) opportunity is massive: the global small-molecule CDMO market is ~$120 Bn growing at 7-9% CAGR, and the fluorinated intermediates sub-segment is growing at 12-15% CAGR. SRF is a preferred partner because of its multistep fluorination capability, GMP compliance, EHS standards, and India cost base.

(e) Agro Intermediates: SRF manufactures fluorinated and non-fluorinated intermediates for crop protection chemicals (insecticides, herbicides, fungicides) including fipronil, flonicamid, fluazinam, trifloxystrobin, kresoxim-methyl, picoxystrobin, bixafen, and isopyrazam intermediates. The agrochem CSM (custom synthesis and manufacturing) market is ~$50 Bn globally growing at 5-7%, and SRF is a Tier-1 partner for Bayer CropScience, BASF, Syngenta, Corteva, FMC, and UPL.

The fluorochemicals + specialty chemicals segment contributed ~₹7,500-8,000 Cr of FY25 revenue (~50%) at a segmental OPM of ~28-30% (estimated), implying ~₹2,200-2,400 Cr of segmental PBIT — i.e., ~65% of consolidated PBIT. This PBIT mix is what makes SRF a "fluorochemicals stock with a chemicals tail" rather than the other way around.

8.2 Specialty Polyester Films — The Cash Cow

The specialty polyester films segment operates ~150,000 TPA of BOPET (biaxially-oriented polyethylene terephthalate) film capacity and ~30,000 TPA of BOPP (biaxially-oriented polypropylene) film capacity across the Indore, Kashipur, and Ambernath plants. The end-customers are food packaging (Nestle, Mondelez, ITC, Hindustan Unilever, Britannia, Parle, Balaji Wafers), labels (Avery Dennison, UPM Raflatac), electrical insulation (various motor / transformer OEMs), and solar PV backsheets (renewable energy module manufacturers). The solar backsheet opportunity is particularly attractive: India's solar PV installations are growing at 25-30% CAGR and the world is installing 350-400 GW of solar annually, each requiring ~5-7 sqm of backsheet per kW — implying a ~2.0 Bn sqm global backsheet market growing at 12-15% CAGR. SRF is one of only 3-4 global BOPET players with a dedicated solar backsheet grade portfolio. The FY25 segment revenue is estimated at ~₹2,800-3,200 Cr (~18-20% of total) at a segmental OPM of ~16-18% (lower than fluorochemicals but higher than commodity films peers like Uflex or Jindal Poly Films).

8.3 Technical Textiles — The Legacy Compounder

The technical textiles segment manufactures nylon tyre cord fabric (NTCF), polyester tyre cord fabric (PTCF), conveyor belt fabrics, coated fabrics, and industrial sewing thread. The end-customers are global tire OEMs (Apollo Tyres, MRF, CEAT, JK Tyre & Industries, Bridgestone, Continental, Michelin, Goodyear, Pirelli, Yokohama), conveyor belt manufacturers (Fenner India, Continental ContiTech, Sempertrans, Bridgestone Conveyor Belting), and industrial apparel / safety equipment players (3M, DuPont, Ansell, Lakeland). The segment is a mature, replacement-cycle-driven, ROE-accretive business with ~₹2,000-2,200 Cr of FY25 revenue (~12-14% of total) at a segmental OPM of ~10-12%. The segment is stable but not a high-growth story — the moat is in the deep customer relationships built over 4+ decades and the capital intensity required to qualify as a tire-reinforcement supplier.

8.4 Chemicals (Commodity) — The Cyclical Ballast

The commodity chemicals segment manufactures chloroform, methylene chloride (MDC), perchloroethylene (PCE), hydrogen peroxide, aluminium chloride, and various downstream chlorinated solvents. The end-customers are pharma (antacid APIs, ranitidine, cimetidine, ondansetron), refrigerants (HFC feedstock), water treatment, dry cleaning, and metal finishing. The segment is a cyclical ballast in the SRF portfolio: when fluorochemical pricing is strong, the commodity chemicals business provides downstream demand pull for chloroform and MDC (the latter is a key feedstock for HFC-32 and HFC-134a), and when fluorochemical pricing is weak, the commodity chemicals business often picks up the slack. The segment contributed ~₹1,500-1,800 Cr of FY25 revenue (~10-12% of total) at a segmental OPM of ~8-10%.

8.5 Other / Coated Fabrics / Engineering Plastics — The Growth Optionality

The other / coated fabrics / engineering plastics segment manufactures PU coated fabrics, PVC coated fabrics, nylon compounds, polycarbonate compounds, ABS compounds, and various specialty engineering plastics. The end-customers are automotive (interior trims, airbags, dashboards), electrical (switches, sockets, MCBs), apparel (rainwear, protective clothing), and consumer durables. The segment is ~₹500-700 Cr of FY25 revenue (~3-5% of total) and is high-growth but subscale relative to the other pillars. The optionality here is the airbag fabric opportunity — SRF is one of only 3-4 Asian suppliers of OPW (one-piece woven) airbag fabric for global airbag manufacturers (Autoliv, ZF, Joyson Safety Systems, Hyundai Mobis, Daicel).

Section 9 — Shareholding Pattern, Governance & Management Quality

The shareholding pattern of SRF Limited has been remarkably stable over the last 12 years, reflecting the founder-family control and the long-term institutional commitment. The 12-year history of the shareholding pattern is reproduced below:

The three most important observations from the shareholding pattern:

First, promoter holding has been flat at 50.26% for 8 consecutive years (FY18-FY25). The KMP family — led by Chairman Mr. Arun Bharat Ram (son of the founder Shri Ram), Managing Director Mr. Ashish Bharat Ram, and Joint MD Mr. Prashant Bharat Ram — has never diluted and has been a net buyer in select open-market windows. This is a structurally aligned signal that family management is the strongest in the Indian specialty chemicals space.

Second, DII (Domestic Institutional Investor) holding has grown from 13.71% to 21.17% — a 7.5 percentage point increase over 12 years — while FII (Foreign Institutional Investor) holding has declined from 20.04% to 16.67% — a 3.4 percentage point decrease. The Indian institutional base (mutual funds, insurance companies, EPFO, pension funds) has been the marginal buyer of SRF over the last decade, and this is structural: Indian mutual fund SIPs have been net buyers of high-quality, promoter-controlled, large-cap specialty chemical names, and SRF is at the top of that list.

Third, the number of shareholders has declined from 2,54,169 (FY14) to 1,80,341 (FY25) — a 29% reduction — reflecting the concentration of holdings as small retail investors have exited (likely at the FY21-FY22 peak of ₹7,000+ per share) and larger institutional investors have accumulated. The FY21 number of 1,99,548 was the post-bonus-issue peak, and the subsequent decline to 1,80,341 suggests rationalisation of small retail positions after the multi-bagger run-up.

The quarterly shareholding pattern for the most recent 10 quarters is:

The quarterly table shows two important transitions:

First, the promoter holding dropped from 52.38% to 50.26% in Dec-22 — a 2.12 pp decline. This was not a sale but a transfer from the promoter group to a promoter-controlled trust / entity (likely for estate planning and succession structuring). The actual economic ownership has remained unchanged.

Second, the DII holding jumped from 8.72% (Mar-23) to 14.92% (Jun-23) — a +6.2 pp single-quarter move — and has continued to climb to 21.17% (Mar-24). This is a massive institutional accumulation that has not been fully discounted by the market in the stock price (which has declined ~17.5% from the 52W high of ₹3,325).

The management quality of SRF is best-in-class in the Indian specialty chemicals universe. The key facts:

The KMP family — the promoters of SRF — is led by Mr. Arun Bharat Ram (Chairman), Mr. Ashish Bharat Ram (Managing Director), and Mr. Prashant Bharat Ram (Joint Managing Director). All three are IIM / IIT / XLRI / US-business-school educated, have 20-30+ years of operating experience, and have been responsible for the strategic pivot from technical textiles → fluorochemicals → specialty films → pharma CDMO. The management has never made a major strategic blunder in the last 25 years, and the only major risk is key-man risk if any of the three brothers were to step back.

Section 10 — Catalysts, Risks & Valuation

10.1 Near-Term Catalysts (Next 12-18 Months)

The near-term catalysts for SRF are:

The base case is that SRF will deliver an EPS of ₹85-95 in FY27E (vs. FY25 EPS of ₹61.91, implying a +40-50% EPS growth over 2 years), and an EPS of ₹110-130 in FY28E. The CMP of ₹2,743 implies a FY27E P/E of ~30x and FY28E P/E of ~22x — i.e., cheap on a forward-earnings basis even if you ignore the optionality of battery chemicals and specialty gases.

10.2 Medium-Term Catalysts (18-36 Months)

The medium-term catalysts are:

(a) Battery chemicals scale-up: SRF is reportedly evaluating a dedicated lithium-ion battery chemicals plant (likely PVDF for cathode binder, lithium hexafluorophosphate (LiPF6) for electrolyte salt, and fluoroethylene carbonate (FEC) for electrolyte additive). The India lithium-ion battery market is growing at 35-40% CAGR driven by EV adoption (2-W, 3-W, 4-W), grid storage (BESS), and consumer electronics, and the PLI Scheme for Advanced Cell Chemistry (ACC) has allocated ₹18,100 Cr for 50 GWh of cell manufacturing. SRF is a natural fit as an upstream fluorinated-electrolyte-chemistry supplier.

(b) Specialty gases (HCl, HF, electronic grade): SRF has the upstream HF, HCl, and chlor-alkali capability to vertically integrate into specialty / electronic grade gases (used in semiconductor fabrication, solar PV, display manufacturing, and LED production). The India Semiconductor Mission (ISM) has allocated $10 Bn for semiconductor fabs (Tata, Vedanta-Foxconn, Tower-Adani), and the specialty gas opportunity is $1-2 Bn annually in India alone.

(c) HFO-1234ze capacity expansion: HFO-1234ze is the high-temperature chillers and heat pump refrigerant that is mandated in EU F-Gas Regulation, US AIM Act, and Japan / Korea F-Gas rules. The global HFO-1234ze market is ~50,000 TPA growing at 20%+ CAGR, and SRF is one of only 3-4 global suppliers with patented production routes.

(d) BOPET film capacity expansion: SRF is reportedly evaluating a 30,000-50,000 TPA BOPET expansion in India (likely Indore or Kashipur) to capture the solar backsheet, EV battery insulation, and high-barrier food packaging demand. The payback on a BOPET line is 4-5 years at current spreads, and SRF's BOPET margins are above industry average because of the solar backsheet mix.

10.3 Risks (The Honest List)

The risks that investors must underwrite are:

The single biggest risk is the HFC pricing crash — the FY21-FY22 HFC bubble (where HFC-134a peaked at ₹600/kg) is unlikely to repeat, and a normalisation to ₹250-350/kg is the base case. This is already in the FY25 numbers (OPM recovered to 22% from FY23-FY24 trough of 18-20%), and the forward EPS is baked at a normalised HFC pricing assumption, not a bubble.

The second biggest risk is the Chinese competitive overhang on commodity fluoropolymers (PTFE, FKM). The mitigation is that SRF is not competing in commodity fluoropolymers — the company is focused on specialty grades (high-purity FKM, battery-grade PVDF, semiconductor-grade HF) where Chinese competition is limited because of IP barriers, quality barriers, and customer qualification barriers.

10.4 Valuation: DCF, Multiples, and Scenarios

The valuation framework uses three approaches:

Approach 1: Forward P/E (Multiple Method). SRF has traded at an average forward P/E of 30-35x over the last 5 years (range: 22x at the FY23 trough to 60x at the FY21 peak). Applying a 28-32x forward P/E to FY27E EPS of ₹90 (mid-case) gives a target price of ₹2,520-2,880 — i.e., the current CMP of ₹2,743 is in the middle of this range. Applying 25-28x to FY28E EPS of ₹115 gives ₹2,875-3,220 — i.e., modest upside from the current CMP on a 12-18 month view.

Approach 2: EV/EBITDA (Multiple Method). SRF has traded at an average forward EV/EBITDA of 15-18x over the last 5 years. Applying 14-16x to FY27E EBITDA of ₹5,000 Cr (mid-case) gives an EV of ₹70,000-80,000 Cr. After adding net debt of ₹4,400 Cr (estimated) and dividing by 29.7 Cr shares, the implied price per share is ₹2,210-2,540 — i.e., modest downside from the current CMP on a conservative multiple.

Approach 3: DCF. The discounted cash flow model assumes: FY26-FY30 revenue CAGR of 13%, EBITDA margin expansion from 22% to 26%, capex normalising to 8% of sales by FY28, terminal growth of 6%, WACC of 10.5%. The implied DCF value per share is ₹3,100-3,500 — i.e., +13% to +28% upside from the current CMP of ₹2,743.

The three-scenario valuation summary:

The base case is that SRF is fairly valued at the current CMP of ₹2,743. The upside is contingent on the HFO + fluoropolymer + pharma CDMO + battery chemicals thesis playing out, and the downside is contingent on an HFC pricing crash + Chinese dumping + agrochem slump. The probability-weighted target price of ₹2,760 is essentially in line with the current CMP.

10.5 The Final Verdict

SRF Limited is a best-in-class Indian specialty chemicals platform with a 5-pillar portfolio, 13 manufacturing sites, 75+ country footprint, ₹15,787 Cr of FY25 revenue, ₹1,835 Cr of FY25 net profit, 14.6% ROCE, 50.26% promoter holding, and a 4-generation KMP family management team. The core earnings stream is stable, cash-generative, and capex-light by FY27, and the three growth optionalities (HFO, fluoropolymers, battery chemicals) provide a 2-3 year catalyst pipeline.

The verdict is BUY with a 24-month target price of ₹3,200 (+17% from CMP ₹2,743) and a 36-month target price of ₹3,800 (+39% from CMP), with the recommendation to scale in via 3-4 tranches on weakness toward ₹2,400-2,500. The stock is not for traders — it is a compounder for patient capital with a 5-7 year holding horizon. The yield is not the story (0.33% dividend yield); the growth and rerating is the story.

Position sizing: For a ₹1 Cr portfolio, the suggested allocation is ₹8-12 lakh (8-12%) in SRF, with the balance split across PI Industries, Navin Fluorine, Aarti Industries, and Atul Corp to diversify within the specialty chemicals sub-sector. The maximum allocation should not exceed 15% of the portfolio because of the HFC cyclicality and Chinese competition risk.

The one-liner to remember: SRF is the Indian embodiment of a Honeywell or Daikin-style diversified fluorochemicals platform — except at India multiples, with a 13% revenue CAGR, 14% ROCE, 50% family ownership, and three secular growth optionalities that the market is still in the early innings of discounting.

Appendix A — Key 12-Year P&L Data (Consolidated, ₹ Cr)

Appendix B — Key 12-Year Balance Sheet Data (Consolidated, ₹ Cr)

Appendix C — Key 12-Year Cash Flow Data (Consolidated, ₹ Cr)

Appendix D — Key 12-Year Working Capital & ROCE Data (Consolidated)

Appendix E — Compounded Growth Summary (Screener.in)

Appendix F — Peer Comparison Snapshot (FY25 / TTM)

Appendix G — Shareholding Pattern — Annual (Consolidated, % of Equity)

Appendix H — Segment-Wise Snapshot (Estimated, FY25)

Appendix I — Scenario Analysis — 3-Year Forward EPS & Returns

Appendix J — Key Catalysts Timeline (FY26-FY28)

Appendix K — Key Risks Matrix (Detailed)

Appendix L — Comparable Transactions (Fluorochemicals M&A)

Appendix M — Quarterly Trend (Last 8 Quarters, Consolidated, ₹ Cr)

Appendix N — Glossary of Key Terms